Table 1 Characteristics of the study participants by SUA tertiles
Variables | Total | SUA, μmol/L | P | Pa | ||
|---|---|---|---|---|---|---|
Tertile 1 (< 341.7) | Tertile 2 (≥ 341.7, < 437.0) | Tertile 3 (≥ 437.0) | ||||
N | 475 | 158 | 158 | 159 | ||
Age, years | 63.00 (54.00–72.00) | 65.00 (56.00–73.00) | 62.00 (54.00–70.75) | 63.00 (53.00–72.00) | 0.556 | NS |
Male, n (%) | 371 (78.11%) | 102 (64.56%) | 131 (82.91%) | 138 (86.79%) | < 0.001 | < 0.001 |
BMI, kg/m2 | 24.09 (22.37–26.56) | 24.43 (22.73–26.77) | 24.03 (22.43–26.39) | 23.72 (22.19–26.08) | 0.191 | NS |
SBP, mm Hg | 124.04 ± 21.42 | 124.15 ± 19.77 | 124.02 ± 22.70 | 123.96 ± 21.82 | 0.997 | NS |
DBP, mm Hg | 75.45 ± 14.09 | 74.94 ± 12.37 | 76.40 ± 14.63 | 75.00 ± 15.16 | 0.583 | NS |
Smoke, n (%) | 226 (47.58%) | 61 (38.61%) | 79 (50.00%) | 86 (54.09%) | 0.017 | 0.047 |
Drink, n (%) | 145 (30.53%) | 38 (24.05%) | 56 (35.44%) | 51 (32.08%) | 0.078 | NS |
Diabetes, n (%) | 93 (19.58%) | 37 (23.42%) | 24 (15.19%) | 32 (20.13%) | 0.179 | NS |
Hypertension, n (%) | 250 (52.63%) | 90 (56.96%) | 77 (48.73%) | 83 (52.20%) | 0.339 | NS |
Gout, n (%) | 11 (2.32%) | 2 (1.27%) | 6 (3.80%) | 3 (1.89%) | 0.296 | NS |
Laboratory results | ||||||
TBIL, μmol/L | 14.12(10.99–19.54) | 13.39 (10.87–18.07) | 14.65 (11.11–20.12) | 14.31 (11.00–19.73) | 0.532 | NS |
DBIL, μmol/L | 3.22 (2.26–4.62) | 3.45 (2.25–4.94) | 3.29 (2.38–4.62) | 3.00 (2.15–4.28) | 0.091 | NS |
IBIL, μmol/L | 10.87 (8.06–15.23) | 10.31 (7.33–14.01) | 11.50 (8.75–15.43) | 11.03 (8.17–15.43) | 0.588 | NS |
ALT, U/L | 31.72 (19.73–51.16) | 28.52 (20.68–43.70) | 30.79 (18.68–49.22) | 35.16 (20.05–56.09) | 0.314 | NS |
AST, U/L | 40.70 (25.00–86.34) | 44.50 (25.40–91.82) | 35.97 (23.61–82.30) | 43.82 (27.45–76.03) | 0.815 | NS |
BUN, mmol/L | 6.14 (5.00–7.92) | 5.69 (4.91–6.73) | 6.27 (4.80–7.85) | 6.97 (5.36–9.28) | < 0.001 | < 0.001 |
CRE, μmol/L | 82.95 (69.05–100.41) | 73.19 (62.70–83.78) | 83.43 (69.70–97.10) | 94.19 (79.96–118.69) | < 0.001 | < 0.001 |
eGFR, mL · min−1 · 1.73 m−2 | 82.54 (65.42–100.38) | 90.30 (74.83–109.60) | 83.88 (70.01–101.75) | 69.80 (50.84–86.82) | < 0.001 | < 0.001 |
TC, mmol/L | 4.44 (3.85–5.38) | 4.31 (3.81–5.07) | 4.55 (3.92–5.38) | 4.59 (3.90–5.47) | 0.997 | NS |
TG, mmol/L | 1.43 (1.04–1.97) | 1.29 (0.97–1.74) | 1.48 (1.08–1.96) | 1.54 (1.10–2.12) | 0.638 | NS |
LDL-C, mmol/L | 2.80 (2.19–3.42) | 2.59 (2.13–3.14) | 2.89 (2.17–3.59) | 2.90 (2.31–3.42) | 0.333 | NS |
HDL-C, mmol/L | 1.00 (0.85–1.17) | 1.03 (0.86–1.21) | 0.99 (0.85–1.14) | 0.96 (0.84–1.13) | 0.244 | NS |
ApoA, g/L | 0.96 (0.82–1.10) | 0.98 (0.82–1.12) | 0.96 (0.85–1.14) | 0.94 (0.81–1.08) | 0.370 | NS |
ApoB, g/L | 0.86 (0.71–1.03) | 0.81 (0.69–0.98) | 0.87 (0.70–1.05) | 0.88 (0.72–1.05) | 0.395 | NS |
Medication use, n (%) | ||||||
Statin use | 0.356 | |||||
ATF10mg/ROS5mg | 3 (0.63%) | 0 (0.00%) | 1 (0.63%) | 2 (1.26%) | NS | |
ATF20mg/ROS10mg | 283 (59.58%) | 97 (61.39%) | 87 (55.06%) | 99 (62.26%) | NS | |
ATF40mg/ROS20mg | 185 (38.95%) | 59 (37.34%) | 70 (44.30%) | 56 (35.22%) | NS | |
β receptor blocker | 421 (88.63%) | 146 (92.41%) | 136 (86.08%) | 139 (87.42%) | 0.175 | NS |
Diuretics | 185 (38.95%) | 45 (28.48%) | 69 (43.67%) | 71 (44.65%) | 0.004 | 0.025 |
Uric-acid-lowering drugs | 8 (1.68%) | 0 (0.00%) | 4 (2.53%) | 4 (2.52%) | 0.132 | NS |
Reevaluation of cholesterol | ||||||
TC (mmol/L) | 3.47 (2.98–4.06) | 3.57 (3.07–4.13) | 3.54 (2.98–4.17) | 3.26 (2.88–3.93) | 0.039 | NS |
TG(mmol/L) | 1.26 (0.94–1.75) | 1.23 (0.92–1.69) | 1.25 (0.94–1.79) | 1.30 (0.96–1.77) | 0.954 | NS |
ApoA(g/L) | 1.01 (0.87–1.17) | 1.09 (0.92–1.23) | 1.01 (0.88–1.14) | 0.97 (0.81–1.12) | 0.012 | 0.030 |
ApoB(g/L) | 0.61 (0.51–0.78) | 0.64 (0.55–0.79) | 0.62 (0.52–0.79) | 0.57 (0.48–0.71) | 0.162 | NS |
HDL-C(mmol/L) | 1.03 (0.88–1.22) | 1.06 (0.93–1.32) | 1.04 (0.88–1.18) | 0.98 (0.83–1.16) | 0.004 | 0.014 |
LDL-C(mmol/L) | 1.82 (1.46–2.29) | 1.88 (1.59–2.24) | 1.81 (1.47–2.36) | 1.71 (1.34–2.29) | 0.050 | NS |
LDL-C control, n (%) | 49 (10.32%) | 8 (5.06%) | 13 (8.23%) | 28 (17.61%) | < 0.001 | 0.006 |